Christoph has over 10 years of experience in drug discovery and preclinical development in the areas of cancer immunotherapy and cancer vaccines, inflammation and asthma, and immuno-safety. Before joining Anaveon, he held leadership positions at Roche, Pfizer and COI Pharmaceuticals. Christoph obtained his PhD in Molecular Biology from the University of Zurich and did his postdoctoral training in B cell immunology and innate immune receptor signaling at The Scripps Research Institute in La Jolla, California.
Search here
Categories
Recent Posts
Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual Meeting
June 5, 2023Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual Meeting
June 3, 2023Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual Meeting
April 18, 2023
Popular Tags
Archives
- June 2023 2
- April 2023 1
- March 2023 2
- February 2023 1
- November 2022 2
- October 2022 1
- September 2022 1
- July 2022 3
- April 2022 1
- March 2022 1
- December 2021 1
- November 2021 1
- June 2021 1
- March 2021 1
- November 2020 1
- May 2020 1
- April 2019 1
- February 2019 1